Purpose:Near-infrared fluorescence-guided surgery (FGS) using cancer-specific tracers is promising for tailored gastric cancer (GC) surgery. Carcinoembryonic antigen (CEA) is a potential target due to its high expression in various digestive cancers, including GC.Materials and Methods:SGM-101, a chimeric anti-CEA monoclonal antibody conjugated with the near-infrared dye BM-104, was evaluated in GC. CEA expression was identified in GC cell lines at the mRNA and protein levels. Xenograft models (MKN-45, SNU-16, SNU-668, 85As2mLuc) were established in mice and injected with SGM-101 or PBS. Biodistribution was monitored using in vivo fluorescence imaging. Tumors were further analyzed by immunofluorescence. In a peritoneal carcinomatosis model, 85As2mLuc cells were injected intraperitoneally, and tumors were evaluated by bioluminescence and fluorescence and histology.Results:MKN-45, SNU-16, and 85As2mLuc were CEA-positive, while SNU-668 was CEA-negative. Flow cytometry confirmed CEA expression: MKN-45 (98%), SNU-16 (85.6%), SNU-668 (6.42%) and 85As2mLuc (78.4%). SGM-101 selectively targeted CEA-expressing tumors, with fluorescence peaking at 48 h, and immunofluorescence verified localization in tumor cells. In the peritoneal models, SGM-101 enabled precise detection of CEA-positive tumors.Conclusions:This study provides the first evidence for the feasibility of SGM-101 in gastric cancer, demonstrating its novelty and translational potential as a cancer-specific imaging agent for fluorescence-guided surgery.
目的：利用癌症特异性示踪剂的近红外荧光引导手术（FGS）为胃癌个体化手术提供了前景。癌胚抗原（CEA）因其在包括胃癌在内的多种消化道癌症中高表达，成为一个潜在靶点。 材料与方法：本研究评估了SGM-101（一种与近红外染料BM-104偶联的嵌合抗CEA单克隆抗体）在胃癌中的应用。首先在mRNA和蛋白水平检测胃癌细胞系中CEA的表达情况。建立小鼠异种移植模型（MKN-45、SNU-16、SNU-668、85As2mLuc），分别注射SGM-101或PBS。通过活体荧光成像监测生物分布，并利用免疫荧光对肿瘤进行进一步分析。在腹膜转移癌模型中，腹腔注射85As2mLuc细胞，通过生物发光、荧光成像及组织学方法评估肿瘤。 结果：MKN-45、SNU-16和85As2mLuc为CEA阳性，而SNU-668为CEA阴性。流式细胞术确认CEA表达率：MKN-45（98%）、SNU-16（85.6%）、SNU-668（6.42%）和85As2mLuc（78.4%）。SGM-101能选择性靶向表达CEA的肿瘤，荧光信号在48小时达到峰值，免疫荧光证实其定位于肿瘤细胞。在腹膜转移模型中，SGM-101实现了对CEA阳性肿瘤的精准检测。 结论：本研究首次为SGM-101在胃癌中的应用可行性提供了证据，证明了其作为癌症特异性成像剂用于荧光引导手术的新颖性和转化潜力。
肿瘤(癌症)患者之家